FDA Submission Update for AXSOME's AUVELITY (NDA215430)
The FDA has received a supplemental application (NDA215430) for AUVELITY from AXSOME, with a standard review priority.
Asset / Drug
Drug and asset intelligence for AXSOME with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.